Biotech Platforms

Sector thesis

Biotech platforms are companies that build the tools, machines, and software that other biotech firms use to discover and develop drugs. Think of them as the picks-and-shovels suppliers of the drug-discovery gold rush. Instead of betting on a single drug candidate, you're betting on the infrastructure that hundreds of companies rely on. The megatrend here is simple: drug discovery is becoming faster and more data-driven. As the cost of sequencing DNA has plummeted and artificial intelligence has improved, the bottleneck has shifted from "can we read genes?" to "can we turn that data into working medicines?" Biotech platforms—whether they're sequencing machines, lab automation, or computational tools—are the answer. More drugs in the pipeline means more demand for these tools, regardless of whether any single drug succeeds or fails. The sector breaks into three main buckets. First, sequencing and genomics tools—machines and software that read and analyze DNA. Second, lab automation and diagnostics—robots and instruments that run experiments faster and cheaper. Third, computational and AI platforms—software that helps predict which drug candidates will work before expensive human trials begin. The biggest risk is that biotech platforms are only as valuable as the biotech industry itself. If funding dries up or drug approvals slow dramatically, demand for these tools drops fast. Also, many platform companies are unprofitable and rely on growth to justify their valuations—a shift in investor appetite for "growth at any cost" can hurt them badly. For a retail portfolio, these are typically longer-term, higher-volatility holdings. Watch for signs of biotech funding health, FDA approval trends, and whether platform companies are expanding their customer base. They work best as a small, diversified position alongside more stable holdings, not as a core bet.